We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y
Read MoreHide Full Article
Theravance Biopharma (TBPH - Free Report) reported fourth-quarter 2017 loss of $1.64 per share, wider than both the Zacks Consensus Estimate of a loss of $1.15 and the year-ago loss of $1.36.
Total revenues in the quarter plunged 21.1% year over year to $4.5 million compared with the prior-year figure. This downside can mainly be attributed to lower sales from the company’s sole marketed product, Vibativ (telavancin). However, the top line surpassed the Zacks Consensus Estimate of $4 million.
Theravance’ shares were down more than 2% on Feb 27 in after-hours trading following the earnings release, which reported wider loss. Moreover, the shares have underperformed the industry in a year’s time. The stock has lost 8.4% versus the industry’s 0.8% increase.
Quarterly Details
Vibativ generated U.S. revenues of $4.1 million in the fourth quarter, down 18% from the year-ago period. Sales decreased mainly due to the impact of generic competition in the United States.
Revenues from collaborations were $0.4 million compared with $0.7 million in the year-earlier quarter.
Research and development expenses were $51 million, up 21.4% from the year-ago period, mainly due to increases in employee-related costs and advancement of the company’s priority pipeline programs, partially offset by reduction in external expenses.
Selling, general & administrative expenses rose 44.6% to $20.9 million, primarily on higher employee-related costs.
2017 Results
Full-year sales slumped 68.3% year over year to $15.4 million. However, the number beat the Zacks Consensus Estimate of $14.5 million.
Full-year loss of $5.45 per share was wider than the year-ago tally of $4.26. Loss was also wider than the consensus mark of a loss of $4.85.
Pipeline and Other Updates
Earlier this February 2018, Theravance entered into a global collaboration agreement with Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , to jointly develop and commercialize its pan-Janus kinase inhibitor, TD-1473, for treatment of inflammatory intestinal diseases.
Pursuant to the above-mentioned contract, Theravance will be entitled to receive an upfront payment of $100 million and be also eligible to get potential payments of $900 million if J&J remains in the collaboration on completion of phase II activities.
Also in January, Theravance along with partner Mylan announced that the new drug application (NDA) for the pipeline candidate, revefenacin (TD-4208), has been accepted by the FDA for treatment of adults with chronic obstructive pulmonary disease. A response from the regulatory body is expected on Nov 13, 2018. The NDA acceptance was supported by positive data from two replicate pivotal phase III efficacy studies and a single 12-month, open-label, active comparator safety trial. In October 2016, the company reported positive data from both the phase III evaluations.
2018 Outlook
Theravance projects operating loss for 2018 in the range of $180-$200 million.
Theravance Biopharma, Inc. Price, Consensus and EPS Surprise
Regeneron’s earnings per share estimates have moved up from $17.13 to $18.65 and from $20.38 to $21.56 for 2018 and 2019, respectively, in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters with an average beat of 9.15%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y
Theravance Biopharma (TBPH - Free Report) reported fourth-quarter 2017 loss of $1.64 per share, wider than both the Zacks Consensus Estimate of a loss of $1.15 and the year-ago loss of $1.36.
Total revenues in the quarter plunged 21.1% year over year to $4.5 million compared with the prior-year figure. This downside can mainly be attributed to lower sales from the company’s sole marketed product, Vibativ (telavancin). However, the top line surpassed the Zacks Consensus Estimate of $4 million.
Theravance’ shares were down more than 2% on Feb 27 in after-hours trading following the earnings release, which reported wider loss. Moreover, the shares have underperformed the industry in a year’s time. The stock has lost 8.4% versus the industry’s 0.8% increase.
Quarterly Details
Vibativ generated U.S. revenues of $4.1 million in the fourth quarter, down 18% from the year-ago period. Sales decreased mainly due to the impact of generic competition in the United States.
Revenues from collaborations were $0.4 million compared with $0.7 million in the year-earlier quarter.
Research and development expenses were $51 million, up 21.4% from the year-ago period, mainly due to increases in employee-related costs and advancement of the company’s priority pipeline programs, partially offset by reduction in external expenses.
Selling, general & administrative expenses rose 44.6% to $20.9 million, primarily on higher employee-related costs.
2017 Results
Full-year sales slumped 68.3% year over year to $15.4 million. However, the number beat the Zacks Consensus Estimate of $14.5 million.
Full-year loss of $5.45 per share was wider than the year-ago tally of $4.26. Loss was also wider than the consensus mark of a loss of $4.85.
Pipeline and Other Updates
Earlier this February 2018, Theravance entered into a global collaboration agreement with Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , to jointly develop and commercialize its pan-Janus kinase inhibitor, TD-1473, for treatment of inflammatory intestinal diseases.
Pursuant to the above-mentioned contract, Theravance will be entitled to receive an upfront payment of $100 million and be also eligible to get potential payments of $900 million if J&J remains in the collaboration on completion of phase II activities.
Also in January, Theravance along with partner Mylan announced that the new drug application (NDA) for the pipeline candidate, revefenacin (TD-4208), has been accepted by the FDA for treatment of adults with chronic obstructive pulmonary disease. A response from the regulatory body is expected on Nov 13, 2018. The NDA acceptance was supported by positive data from two replicate pivotal phase III efficacy studies and a single 12-month, open-label, active comparator safety trial. In October 2016, the company reported positive data from both the phase III evaluations.
2018 Outlook
Theravance projects operating loss for 2018 in the range of $180-$200 million.
Theravance Biopharma, Inc. Price, Consensus and EPS Surprise
Theravance Biopharma, Inc. Price, Consensus and EPS Surprise | Theravance Biopharma, Inc. Quote
Zacks Rank & Key Pick
Theravance carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Regeneron Pharmaceuticals (REGN - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have moved up from $17.13 to $18.65 and from $20.38 to $21.56 for 2018 and 2019, respectively, in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters with an average beat of 9.15%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>